Jubilant Pharmova shares rallied 4% after the company reported robust financial results for Q4 FY25, highlighting a sharp turnaround in profitability and operating margins. As of 1:57 PM, the shares were trading 3.58% higher at Rs 938.00.
The pharma major posted a consolidated net profit of ₹151.3 crore for the quarter ended March 31, 2025, a significant rebound from a net loss of ₹61.8 crore in the same period last year. This impressive turnaround was driven by strong operational performance across key business segments.
Revenue from operations in Q4 FY25 rose to ₹1,928.8 crore, marking a year-on-year growth of nearly 10% from ₹1,758.6 crore in Q4 FY24. Jubilant Pharmova’s EBITDA also saw a healthy rise to ₹345 crore from ₹271 crore, while EBITDA margin improved to 18% from 15.43%, indicating enhanced cost efficiency and operational leverage.
For the full financial year FY25, the company recorded a consolidated net profit of ₹836.3 crore, a remarkable increase from ₹72.7 crore in FY24. Total income for the year climbed to ₹7,291.3 crore, compared to ₹6,771.6 crore in the previous fiscal.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.